Human Health Portfolio enGene, Inc. and Forbion European Acquisition Corp. (“FEAC”, Nasdaq: FRBN) Announce Business Combination Agreement to Create Nasdaq-Listed Biotechnology Company Developing Next-Generation Non-Viral, Locally Administered Gene Therapies maggio 17, 2023
Human Health Company Forbion closes the initial public offering of 11.0 million units of Forbion European Acquisition Corporation (FEAC) on the Nasdaq Global Market dicembre 14, 2021